MGB welcomes O'Neill Report findings on antibiotics
Released: Friday 15th May 2015
Glasgow, Scotland, 15th May 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, endorses the latest report from Jim O’Neill’s Review on Antimicrobial Resistance and welcomes the idea of a global AMR Innovation fund.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “We are pleased that the major problem of antimicrobial resistance is now receiving the attention it clearly deserves. The figures contained in Jim O’Neill’s report, and in particular the potential human cost of not addressing antibiotic resistance, are alarming. The need for novel and differentiated products to tackle antimicrobial resistance is clear and requires new and radical thinking from a broad range of stakeholders.